To include your compound in the COVID-19 Resource Center, submit it here.

Elan down on generic approval

ELN was off $0.40 (12%) to $2.88 on 7.7 million shares

Read the full 111 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE